Indeed, recent updated guidance published by the European Association for the Study of Diabetes (EASD), followed in Portugal, indicated GLP-1 receptor agonists or SGLT-2 inhibitors as second-line therapies (following metformin) in patients with type 2 diabetes with high risk of atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease [7, 8]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.